「先駆け審査指定制度」の対象品目を初めて指定しました｜厚生労働省
https://www.mhlw.go.jp/stf/houdou/0000102009.htmlBundle the HTML, screenshot, summaries, and metadata into one ZIP file. Pro saves automatically start preparing the external RFC 3161 timestamp, and only unfinished records need one more preparation step before download.
「先駆け審査指定制度」の対象品目を初めて指定しました｜厚生労働省
Open the dedicated viewer to inspect the saved page with archive metadata pinned above it.
This is a self-contained HTML copy with CSS and images embedded, so it still renders even if the original page disappears.
The dedicated viewer keeps the original URL and saved timestamp visible while you review the archived HTML.
This page announces that Japan's Ministry of Health, Labour and Welfare has designated six pharmaceutical products for the first time under the "Breakthrough Therapy Designation System." The system was introduced to accelerate drug development and approval for innovative new medications treating serious diseases. It shortens the standard review period from 12 months to 6 months through priority consultation, enhanced pre-evaluation, and expedited review. The six designated drugs target various conditions including tuberous sclerosis complex, Duchenne muscular dystrophy, influenza, hereditary angioedema, acute myeloid leukemia, and gastric cancer.
